An important achievement has been achieved by the BIOGENERA Research Team, concerning the scientific publication of an article in the prestigious international journal “Journal of Experimental & Clinical Cancer Research.” The article titled “The MYCN inhibitor BGA002 restores the retinoic acid response leading to differentiation or apoptosis by the mTOR block in MYCN-amplified Neuroblastoma” is about the effects obtained in preclinical studies by the new drug BGA002 for the treatment of Neuroblastoma (the deadliest extracranial tumor in children). In particular, research has shown that the new drug BGA002 is able to reactivate the anti-tumor response of the drug Retinoic Acid (a vitamin A derivative), creating a synergistic effect and a powerful therapeutic response even for cases of Neuroblastoma with MYCN gene amplification (which fall into high-risk cases).
The publication is titled “The MYCN inhibitor BGA002 restores the retinoic acid response leading to differentiation or apoptosis by the mTOR block in MYCN-amplified neuroblastoma.”
link to article
https://pubmed.ncbi.nlm.nih.gov/35490242/
Download article
